MedTrace Logo

Promoting Blood Pressure Control and Cholesterol Reduction to Prevent Major Complications in Persons With Diabetes

NCT00210262 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL

Last updated 2005-09-21

No results posted yet for this study

Summary

Diabetes mellitus (DM) imposes a significant burden of early mortality and decreased quality of life on the 6% of Canadians affected by it. There is a growing body of research evidence showing that the use of certain medications (ACE inhibitors, blood pressure medications and cholesterol lowering agents) can reduce the major complications of diabetes such as heart, blood vessel and kidney disease and amputations. Unfortunately this research knowledge does not appear to be routinely translated into clinical practice. The proposed study examines the effect of simple mailed interventions to patients or physicians on improving the use of these therapies. The strategies to be tested are direct patient education with an emphasis on blood pressure and lipid control rather than use of particular drugs and, for physicians, the provision of confidential prescribing feedback together with targeted educational bulletins. With patient and physician consent, health care administrative data will be used to examine the impact of the interventions. If successful, the study will identify low cost reproducible interventions to promote the use of proven preventive therapies in clinical practice.

Conditions

Interventions

BEHAVIORAL

Feedback and Education

Sponsors & Collaborators

  • Institute for Clinical Evaluative Sciences

    lead OTHER

Principal Investigators

  • Janet E. Hux, MD, SM · ICES

Study Design

Allocation
RANDOMIZED
Purpose
ECT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-10-31
Completion
2005-01-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00210262 on ClinicalTrials.gov